The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients

Table 5

The effects of thiazolidinediones on blood lipids in comparative studies with HIV infected, HAART-treated patients. HDL = high-density lipoprotein, LDL = low-density lipoprotein, NS = nonsignificant, NR = not reported, CI = confidence interval.

𝑁	Drug	Duration	Total cholesterol (mmol/L)	HDL cholesterol (mmol/L)	LDL cholesterol (mmol/L)	Triglycerides (mmol/L)	Reference
30	Rosi versus placebo	24 weeks	Rosi: +1.4, ^∗𝑃<.01; pla: 0.0, ^∗NSΔ rosi versus pla NS	NS	NR	NS At 12 weeks: rosi: +3.0, ^∗𝑃<.05; pla: NS	Sutinen et al. [55]
108	Rosi versus placebo	48 weeks	Rosi: +0.9; pla: 0.0 Δ Rosi versus pla 𝑃<.001	NS	Rosi: +0.8; pla: +0.4 Δ rosi versus pla 𝑃=.04	Rosi: +1.5; pla: +1.3 Δ rosi versus pla 𝑃=.04	Carr et al. [56]
14	Pio versus feno versus pio + feno versus placebo	12 months	NS	pio: +0.15, ^∗NS; pla: −0.20, ^∗NSΔ pio versus pla 𝑃=.01	Pio: +1.7, ^∗𝑃=.07; pla: −0.6, ^∗NS	NS	Gavrila et al. [65]
96	Rosi versus placebo	24 weeks	NS	NS	NS	NS	Cavalcanti et al. [62]
28	Rosi versus placebo	3 months	Rosi: +0.6; pla: −0.4Δ rosi versus pla 𝑃=.007	NS	Rosi: +0.4; pla: −0.4Δ rosi versus pla 𝑃=.01	NS	Hadigan et al [57]
105	Rosi versus metformin versus rosi + met versus placebo	16 weeks	Rosi: +0.4, ^∗𝑃<.05; all other groups ^∗NS	Rosi: −0.1, ^∗𝑃<.001; all other groups ^∗NSΔ rosi versus pla 𝑃=.005; Δ rosi versus rosi + met 𝑃=.006	Rosi: +0.2, ^∗𝑃<.05; all other groups ^∗NSΔ rosi versus pla 𝑃=.048	NS	Mulligan et al. [60]
130	Pio versus placebo	48 weeks	NS	Pio: +0.09; pla: −0.08Δ pio versus pla 𝑃=.005	NS	NS	Slama et al. [66]
37	Rosi versus placebo	6 months	NS	NR	NR	NS	Haider et al. [61]
39	Rosi versus metformin	26 weeks	Rosi: +0.4, ^∗NS; met: −0.4, ^∗𝑃<.05Δ rosi versus met 0.8 (95% CI, 0.3 to 1.3)	Rosi: −0.15, ^∗𝑃<.05; met: +0.01, ^∗NSΔ rosi versus met 0.16 (95% CI, −0.35 to −0.02)	Rosi: +0.2, ^∗NS: met: −0.4, ^∗𝑃<.05Δ rosi versus met 0.6 (95% CI, 0.2 to 1.1)	Rosi: +0.5, ∗versus <0.05; met: −0.6, ^∗𝑃<.05Δ rosi versus met 1.1 (95% CI, 0.4 to 2.6)	van Wijk et al. [58]

∗denotes significance within the study group compared to baseline value, Δ denotes comparison of the change between respective study groups.